Form D · Biotechnology
ARTMS Inc.
Vancouver, A1 · CIK 0001812505
Offering snapshot reported May 26, 2020 · SEC filing
- Reported sold
- $4.83M Offering amount: $13.1M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 8, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 26, 2020 | Initial | $4,832,787 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-367656
"Total Amount Sold" reflects the Initial Closing. "Total Offering Amount" and "Total Remaining to be Sold" includes securities to be sold in connection with the First Milestone Closing and Second Milestone Closing, each of which have yet to occur.
Source: Form D, filed May 26, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Charles S. Conroy | Director, Executive |
| Michael Cross | Executive |
| Karimah Es Sabar | Director |
| Steven Foster | Director, Executive |
| Steven Hochberg | Director |
| Paul Schaffer | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4250 Wesbrook Mall
Vancouver, A1, V6T 1W5
Vancouver, A1, V6T 1W5